Regeneron Pharmaceuticals (REGN)
$498.84 6.29 (1.25%)
18:33 EST REGN Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 52.85B
PE Ratio 40.42
Volume (Avg. Vol.) 964,026
Day's Range 497.12 - 509.54
52-Week Range 328.13 - 664.64
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.
As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.
REGN stock is shifting the market today thanks to news its coronavirus treatment received emergency FDA approval.
Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives. With them, we can solve Covid-19.
The U.S. government has pulled out all the stops to develop a treatment for Covid-19. These biotech stocks are leading the race for a cure.
Investors are banking on an upsurge in pharmaceutical stocks once various vaccines and other therapies gain commercial approval from the U.S. Food and Drug Administration (FDA). Here is a list of pharmaceutical companies that stand to benefit in the coming months.
With Trump's support, Regeneron just filed for emergency-use authorization with the FDA. REGN stock is climbing on the news.
As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions.
Square, Regeneron, Aphria and Tilray were our top stock trades for Tuesday. That said, here's how the charts look after Monday's action.
Regeneron Pharmaceuticals (REGN) stock is soaring Monday on news that its treatment for the coronavirus was used on President Trump.
A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.
Coronavirus vaccines get all the attention, but these four pharmaceutical stocks benefit from equipment, drug and test kit developments.
Investors are excited about Regeneron stock for its Covid-19 treatment. They're missing the point. Regeneron is a great long-term buy.
It may be time to continue selling in May, but not for these all-star earnings stocks to buy. Here's why each stands out from the crowd.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
Despite a year-to date drop of -13.9%, the S&P 500 could still be overpriced by 35%. If the S&P 500 is overvalued, component stocks must be.
In times like this, investors are better off focusing on large-cap stocks that offer size, capital and products the economy truly relies on.
Navellier RatingsPowered by Portfolio Grader